These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 39125707)

  • 1. ADAMTS13 in the New Era of TTP.
    Papakonstantinou A; Kalmoukos P; Mpalaska A; Koravou EE; Gavriilaki E
    Int J Mol Sci; 2024 Jul; 25(15):. PubMed ID: 39125707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in thrombotic thrombocytopenic purpura.
    Sadler JE; Moake JL; Miyata T; George JN
    Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura.
    Kubo M; Matsumoto M
    Int J Hematol; 2023 Mar; 117(3):331-340. PubMed ID: 36757521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
    Matsumoto M; Miyakawa Y; Kokame K; Ueda Y; Wada H; Higasa S; Yagi H; Ogawa Y; Sakai K; Miyata T; Morishita E; Fujimura Y;
    Int J Hematol; 2023 Nov; 118(5):529-546. PubMed ID: 37689812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
    Shenkman B; Einav Y
    Autoimmun Rev; 2014; 13(4-5):584-6. PubMed ID: 24418304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.
    Béranger N; Benghezal S; Savigny S; Capdenat S; Joly BS; Coppo P; Stepanian A; Veyradier A
    Thromb Res; 2019 Sep; 181():29-35. PubMed ID: 31330376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombotic Thrombocytopenic Purpura --Pathophysiology and Assays of ADAMTS13 Activity].
    Kato S; Fujimura Y
    Rinsho Byori; 2015 Oct; 63(10):1228-36. PubMed ID: 26897861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Overview of Laboratory Testing for ADAMTS13.
    Favaloro EJ; Pasalic L
    Methods Mol Biol; 2023; 2663():481-486. PubMed ID: 37204731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.
    Joly BS; Coppo P; Veyradier A
    Expert Rev Hematol; 2019 Jun; 12(6):383-395. PubMed ID: 31107120
    [No Abstract]   [Full Text] [Related]  

  • 11. [Thrombotic thrombocytopenic purpura - a rare diagnosis].
    Einarsdottir S; Rosander C; Frändberg S; Dezfoolian H; Lisak M
    Lakartidningen; 2023 Sep; 120():. PubMed ID: 37712566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies.
    Crawley JT; Scully MA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():292-9. PubMed ID: 24319194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis.
    El Otmani H; Frunt R; Smits S; Barendrecht AD; de Maat S; Fijnheer R; Lenting PJ; Tersteeg C
    Blood; 2024 May; 143(20):2089-2098. PubMed ID: 38271661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.
    Bowyer A; Brown P; Hopkins B; Scully M; Shepherd F; Lowe A; Mensah P; Maclean R; Kitchen S; van Veen JJ
    Br J Haematol; 2022 May; 197(3):349-358. PubMed ID: 35262910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of ADAMTS13 Inhibitors in Acquired TTP.
    Favaloro EJ; Chapman K; Mohammed S; Vong R; Pasalic L
    Methods Mol Biol; 2023; 2663():505-521. PubMed ID: 37204733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP.
    Schwameis M; Schörgenhofer C; Assinger A; Steiner MM; Jilma B
    Thromb Haemost; 2015 Apr; 113(4):708-18. PubMed ID: 25503977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathogenesis and novel treatment of thrombotic thrombocytopenic purpura].
    Matsumoto M
    Rinsho Ketsueki; 2021; 62(5):480-485. PubMed ID: 34248125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [ADAMTS13, von Willebrand factor specific cleaving protease].
    Veyradier A; Coppo P
    Med Sci (Paris); 2011 Dec; 27(12):1097-105. PubMed ID: 22192749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Diagnosis and treatment of thrombotic thrombocytopenic purpura].
    Kubo M; Matsumoto M
    Rinsho Ketsueki; 2020; 61(5):529-535. PubMed ID: 32507820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.